lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


12345678910111213...4546»
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
    Journal:  The binding mechanism of failed, in processing and succeed inhibitors target SARS-CoV-2 main protease. (Pubmed Central) -  Nov 13, 2024   
    By gaining insights into the dynamics, we can potentially elucidate why lopinavir/ritonavir, initially considered promising, failed to effectively treat COVID-19. Furthermore, understanding the mechanistic aspects of N3 and NMV inhibition on SCM not only contributes to rational drug discovery against COVID-19 but also aids future studies on the catalytic mechanisms of main proteases in other novel coronaviruses.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis. (Pubmed Central) -  Oct 30, 2024   
    Furthermore, understanding the mechanistic aspects of N3 and NMV inhibition on SCM not only contributes to rational drug discovery against COVID-19 but also aids future studies on the catalytic mechanisms of main proteases in other novel coronaviruses.Communicated by Ramaswamy H. Sarma. Furthermore, this study examines the published literature about the pharmacological interventions for the novel coronavirus disease 2019 (COVID-19), explicitly focusing on the safety and effectiveness of different medications such as Remdesivir (marketed as Veklury
  • ||||||||||  hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Enrollment change, Trial termination:  Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 (clinicaltrials.gov) -  Aug 27, 2024   
    P1/2,  N=6, Terminated, 
    We also performed cytotoxicity assay to confirm that these compounds are not toxic to human cells. N=40 --> 6 | Recruiting --> Terminated; Stopped by the IP, because the first 6 patients recruited had died and it was unknown if it represented any safety risk or if the sample was insufficient to evaluate the study hypotesis.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors. (Pubmed Central) -  Aug 22, 2024   
    We used kinetic antibody data from the lopinavir-ritonavir trial conducted at Jin Yin-Tan Hospital in January 2020, which involved adults hospitalized with severe COVID-19 (LOTUS, ChiCTR2000029308)...Our findings suggested that corticosteroid therapy was associated with impaired initiation of the antibody response but this did not compromise the peak titres of binding and neutralizing antibodies. Throughout the decay phase, from the acute phase to the half-year follow-up visit, short-term and low-dose corticosteroids did not significantly affect humoral responses, except for accelerating the waning of short-lived antibodies.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Factors Influencing the Use and Demand of New Coronavirus Therapy Drugs Among the Adults During COVID-19 in China. (Pubmed Central) -  Aug 13, 2024   
    Most people only need some antiviral drugs such as lopinavir/ritonavir or Chinese herbal preparations for treatment...Therefore, governments should prioritize vulnerable groups when formulating drug policies and target drug literacy and guidance. In addition, it is recommended that a drug distribution system be set up within the community so that those in need can have quick and easy access to drugs.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports. (Pubmed Central) -  Aug 4, 2024   
    Multidrug therapy is effective because of the differing mechanisms of action of these drugs, and it may also mitigate the emergence of drug-resistant SARS-CoV-2 strains. The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl).
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard
    Journal:  QSPR/QSAR study of antiviral drugs modeled as multigraphs by using TI's and MLR method to treat COVID-19 disease. (Pubmed Central) -  Jun 8, 2024   
    The primary objective is to showcase the valuable contribution of multigraphs to QSPR and QSAR analyses, offering crucial insights into molecular structures and antiviral properties. The integration of physicochemical applications enhances our understanding of factors influencing antiviral drug efficacy, essential for combating emerging viral strains effectively.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Trial completion date, Trial primary completion date:  Lopinavir/Ritonavir in PLWH With High-Grade AIN (clinicaltrials.gov) -  May 27, 2024   
    P1,  N=21, Recruiting, 
    Although protease inhibitor-based ART was associated with increases in inflammation, factors other than inflammation likely explain the increased PTD in ART-based regimens compared with zidovudine alone. Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Prezista (darunavir) / J&J, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    FDA event, Review, Journal:  Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature. (Pubmed Central) -  May 27, 2024   
    In this article, several COVID19-related discussions have been provided including emerging variants of concern of, COVID19 pathogenesis, COVID19 pandemic scenario in Saudi Arabia, drug repurposing strategies against SCV-2, as well as repurposing of US FDA-approved antiviral drugs that might be considered to combat SCV-2 in Saudi Arabia. Moreover, drug repurposing in the context of COVID19 management along with its limitations and future perspectives have been summarized.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Transitioning children to pediatric dolutegravir (TORPEDO) study: endline results in Benin, Nigeria and Uganda (Poster board: 532) -  May 2, 2024 - Abstract #AIDS2024AIDS_2861;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Improved growth during bNAb-only treatment among early-treated suppressed children with HIV (Poster board: 136) -  May 2, 2024 - Abstract #AIDS2024AIDS_1471;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  The interplay of poorly soluble drugs in dissolution from amorphous solid dispersions. (Pubmed Central) -  Apr 8, 2024   
    The co-formulation of two amorphous drugs can be accompanied by an immense increase in the complexity of the system as exemplarily reported for ritonavir and lopinavir embedded in a composite polymer matrix of PVPVA...In addition, the use of different grades of HPMCAS demonstrated the possibility to further modify the dissolution profile. For a preliminary biorelevant assessment, the selected formulations were tested in a biphasic dissolution setup.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    No Early Signal That DTG Improves 24-Week Viral Suppression in Infants in Botswana (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_1328;    
    Background: The World Health Organization recommends dolutegravir (DTG)-based 3-drug antiretroviral therapy (ART) in children >4 weeks weighing >3kg. DTG-based ART achieves rapid viral load decline in adults and low rates of treatment failure in older children, but outcomes for children treated from birth, a time when adherence challenges are of particular concern, are limited.We compared prevalence of 24-week HIV-1 RNA suppression in early-treated children on lopinavir-ritonavir (LPV/r)
  • ||||||||||  nevirapine / Generic mfg., abacavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Sex Differences in Growth Trajectories Between Early-Treated Infants With HIV and Controls (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_748;    
    This pattern was observed despite boys having consistently lower anthropometric parameters than girls in both groups. Factors responsible for this sex difference are not clear, but early ART initiation and/or perinatal infection appears have a differential impact on growth according to sex.
  • ||||||||||  abacavir/lamivudine/lopinavir/ritonavir (ABC/3TC/LPV/r) / Cipla, DNDi
    1 in 5 Sub-Saharan Infants Switches From Undetectable to Detectable HIV Viral Load During Follow-Up (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_746;    
    Undetectable VL increased across time, but oscillations between undetectable and detectable VL in the long term were frequent. This underscores the need for further investigations to assess the potential clinical implications of these fluctuations on patient outcomes and the size of the viral reservoir.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Retrospective data, Review, Adverse events:  Comparative risk of adverse perinatal outcomes associated with classes of antiretroviral therapy in pregnant women living with HIV: systematic review and meta-analysis. (Pubmed Central) -  Mar 13, 2024   
    Integrase strand transfer inhibitor (INSTI) dolutegravir (DTG)-based antiretroviral therapy (ART) is recommended by World Health Organisation as preferred first-line regimen in pregnant women living with human immunodeficiency virus (HIV) (WLHIV)...Specifically, lopinavir/ritonavir (LPV/r) was associated with an increased risk of SGA (RR 1.40, 95% CI [1.18, 1.65], p?=?0.003) and VSGA (RR 1.84, 95% CI [1.37, 2.45], p?=?0.002), compared to efavirenz, but not compared to nevirapine...Our findings support the recommendation of INSTI-ART as first-line ART regimen for use in pregnant WLHIV. However, the increased risks of SGA and VGSA associated with PI-ART, compared to NNRTI-ART, may impact choice of second- and third-line ART regimens in pregnancy.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42021248987.
  • ||||||||||  Enrollment change:  REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) -  Feb 28, 2024   
    P3,  N=20000, Recruiting, 
    Azithromycin was the second most prescribed drug in Q1 2020 and became the top when it was added to the guidelines as a candidate in Q2 2020...Dexamethasone was the top from Q3 2020, when the recommendation of steroid changed to specify dexamethasone, to Q1 2022 (prescribed to 2,887 N=10000 --> 20000
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Biomarker, Trial completion date, Trial primary completion date:  LUSZ_CTS_COVID: LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=1000, Recruiting, 
    N=10000 --> 20000 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Retrospective data, Journal:  Impact of Using Antiviral Therapy on COVID-19 Progression in ICU Patients: A Saudi Arabian Retrospective Analysis. (Pubmed Central) -  Feb 12, 2024   
    Remdesivir and ribavirin use were linked to gender and Saudi nationality, while oseltamivir was related to gender, Saudi nationality, and body mass index...The findings highlight the significance of tailoring treatment strategies based on patient characteristics and viral history. These insights contribute to a deeper understanding of COVID-19 management and can inform clinical decision-making and further research in this field.
  • ||||||||||  favipiravir / Generic mfg.
    Review, Journal:  Favipiravir for treating COVID-19. (Pubmed Central) -  Feb 9, 2024   
    The low- to very low-certainty evidence means that we do not know whether favipiravir is efficacious in people with COVID-19 illness, irrespective of severity or admission status. Treatment with favipiravir may result in an overall increase in the incidence of adverse events but may not result in serious adverse events.